Key result
Higher atherogenic index of plasma is linked to ~2.1-fold higher risk of cognitive impairment.
Why the study?
The atherogenic index of plasma is a reliable marker of atherogenic dyslipidemia, but prospective evidence on its association with cognitive impairment and Alzheimer's disease biomarkers in older adults was limited.
Does a higher atherogenic index of plasma increase the risk of incident cognitive impairment and memory decline in adults aged ≥ 65 years?
Cohort (n=1,143)
Does a higher atherogenic index of plasma increase the risk of incident cognitive impairment and memory decline in adults aged ≥ 65 years?
Higher atherogenic index of plasma is independently associated with an increased risk of incident cognitive impairment and faster memory decline in older adults, especially when combined with elevated p-tau181 and in APOE ε4 carriers.
Answers are grounded in this paper and cite their sources.
AIP may aid cognitive risk stratification in older adults; hypothesis-generating and requires interventional confirmation before practice change.
Introduction: The atherogenic index of plasma (AIP) is a reliable marker of atherogenic dyslipidemia, but prospective evidence on its association with cognitive impairment in older adults is limited. We examined whether AIP was associated with incident cognitive impairment, and explored associations with plasma Alzheimer’s disease (AD) biomarkers and apolipoprotein E (APOE) ε4 status. Methods: This study included 1,143 adults aged ≥ 65 years from the Hubei Memory and Aging Cohort Study. AIP was calculated as log(triglyceride/high-density lipoprotein cholesterol). The association of AIP with incident cognitive impairment and its joint effects with plasma AD biomarkers were evaluated using Cox models. Dose-response associations were assessed by restricted cubic splines. Cognitive domain declines were analyzed using linear mixed-effects models. Analyses were stratified by APOE ε4 status. Results: After adjustment, higher baseline AIP was independently associated with greater risk of cognitive impairment, showing a nonlinear dose-response relationship (inflection point: 0.758). Compared to the lowest quartile, the highest quartile exhibited a higher risk (Hazard Ratio [HR] = 2.15; 95% Confidence Interval [CI]: 1.47–3.12). Higher AIP also correlated with faster memory decline (β = −0.14, 95% CI: −0.26 to −0.01). Participants with higher AIP and elevated p-tau181 had an increased risk of cognitive impairment (HR = 3.46, 95% CI: 1.58–7.61). These effects were more pronounced among APOE ε4 carriers. Conclusions: Higher AIP was associated with cognitive impairment and faster memory decline. High AIP combined with elevated p-tau181 was associated with greater risk, particularly among APOE ε4 carriers, supporting refined risk stratification in older adults.
No takes yet. Share an insight, caveat, or question.
Xie et al. (2026) conducted a cohort in Cognitive impairment (n=1,143). Higher atherogenic index of plasma (AIP, highest quartile) vs. Lowest quartile of atherogenic index of plasma (AIP) was evaluated on Incident cognitive impairment (HR 2.15, 95% CI 1.47-3.12). Higher baseline atherogenic index of plasma (highest vs. lowest quartile) was independently associated with a greater risk of cognitive impairment.
Synapse has enriched 10 related papers. Consider them for comparative context: